Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

740 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Current status of HER2 testing.
Di Leo A, Dowsett M, Horten B, Penault-Llorca F. Di Leo A, et al. Among authors: dowsett m. Oncology. 2002;63 Suppl 1:25-32. doi: 10.1159/000066204. Oncology. 2002. PMID: 12422052 Review.
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team. Piccart-Gebhart MJ, et al. Among authors: dowsett m. N Engl J Med. 2005 Oct 20;353(16):1659-72. doi: 10.1056/NEJMoa052306. N Engl J Med. 2005. PMID: 16236737 Free article. Clinical Trial.
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.
Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sánchez Rovira P, Piccart-Gebhart MJ; HERA study team. Smith I, et al. Among authors: dowsett m. Lancet. 2007 Jan 6;369(9555):29-36. doi: 10.1016/S0140-6736(07)60028-2. Lancet. 2007. PMID: 17208639 Clinical Trial.
HER2 testing in the UK: consensus from a national consultation.
Dowsett M, Hanby AM, Laing R, Walker R; National HER2 Consultation Steering Group. Dowsett M, et al. J Clin Pathol. 2007 Jun;60(6):685-9. doi: 10.1136/jcp.2006.044321. Epub 2007 Feb 23. J Clin Pathol. 2007. PMID: 17322344 Free PMC article.
Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.
Dowsett M, Procter M, McCaskill-Stevens W, de Azambuja E, Dafni U, Rueschoff J, Jordan B, Dolci S, Abramovitz M, Stoss O, Viale G, Gelber RD, Piccart-Gebhart M, Leyland-Jones B. Dowsett M, et al. J Clin Oncol. 2009 Jun 20;27(18):2962-9. doi: 10.1200/JCO.2008.19.7939. Epub 2009 Apr 13. J Clin Oncol. 2009. PMID: 19364966 Free PMC article. Clinical Trial.
Emerging technologies for assessing HER2 amplification.
Penault-Llorca F, Bilous M, Dowsett M, Hanna W, Osamura RY, Rüschoff J, van de Vijver M. Penault-Llorca F, et al. Among authors: dowsett m. Am J Clin Pathol. 2009 Oct;132(4):539-48. doi: 10.1309/AJCPV2I0HGPMGBSQ. Am J Clin Pathol. 2009. PMID: 19762531 Review.
740 results